Non-metastatic Pancreatic Cancer: Resectable, Borderline Resectable, and Locally Advanced-Definitions of Increasing Importance for the Optimal Delivery of Multimodality Therapy

A patient-level meta-analysis of FOLFIRINOX for locally advanced pancreatic cancer.

“…Considerable heterogeneity across studies in the percentage of resection is explained by lack of consensus in the literature on selecting patients for resection after FOLFIRINOX. (49) No significant correlation was found across studies between the percentage of resection and OS. However, this analysis was not performed at the patient level.…”

Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer

“…This was a retrospective analysis of a prospectively maintained database which included consecutive patients with resectable and BLR PC who received neoadjuvant therapy and surgery for pancreatic adenocarcinoma at a single academic institution from 2009 to 2018. Clinical stage at the time of diagnosis was determined using objective radiographic criteria based on computed tomography (CT) imaging, as previously described (14,15). This study was approved by the Institutional Review Board of the Medical College of Wisconsin.…”

Vascular Resection for Pancreatic Cancer: 2019 French Recommendations Based on a Literature Review From 2008 to 6-2019

“…A recent study (17) has shown that a standardized pathological protocol R0-resection based on 1 mm clearance was rarely achieved after upfront venous resection due to microscopic involvement of the SMV-groove (LE 4). It is important to note that patients considered to be at high risk of R1 resection and/or those with an unfavorable clinical and/or "biological" status are now candidates for neoadjuvant therapy (18)(19)(20)(21)(22)(23)(24)(25)(26) (LE 3). In one North American study (27) the benefits of neoadjuvant therapy were found to be significant in the presence of "unilateral" venous involvement (Ishikawa II-III) (LE 3).…”